Treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and NS3A (non-structural protein 3A) protease inhibitor simeprevir resulted in high rates of sustained virological response in chronic…
large sector of the HCV patients population. High response rate to treatment with Sofosbuvir and Daclatasvir necessitated confirmation of total cure through excluding HCV occult infection ... estimate the occurrence of…
Objectives: to determine the efficacy of (Sofosbuvir/ledipasvir) in treating children with HCV infection. Patients and methods: Patients with positive HCV PCR, aged 7 to 18 years were enrolled. History ... clinical…
IVIG, Rituximab, Bortezumib, methylprednisone (500 mg x3), and total plasma exchange. Patient started on sofosbuvir and simeprevir without ribavirin for 12 weeks. HCV RNA at: Week
naïve patients with chronic hepatitis C(CHC) genotype 3(G-3) infection without cirrhosis, sofosbuvir plus daclatasvir daily for 12 weeks is the recommended therapy. In patients ... study the SVR rates in CHC G3 patients…
caused patients to respond or not during sofosbuvir treatment. Methods: Using reverse transcriptase-PCR technology, patients in our study were split into two groups: Those who were anti-HCV positive ... negative (n=55)…
Ultra-performance liquid chromatographic (UPLC) method, for ledipasvir and sofosbuvir determination in bulk mixtures, and in tablets was developed and validated. The determination of the drugs, ledipasvir and sofosbuvir…
Sofosbuvir (SOF) is a widely used drug for treatment of chronic hepatitis C while paracetamol (PAR) is the recommended analgesic for patients with hepatitis C because of its effectiveness
sensitive, specific and economic spectrophotometric method was developed and validated for simultaneous quantitation of sofosbuvir and velpatasvir in tablet dosage form. New method based on the simultaneous estimation…
most common reason for liver transplants in the United States. Recent advances with sofosbuvir/ribavirin or ledipasvir/sofosbuvir have confirmed to be successful in eradicating HCV with minimal ... severe side effects…
Objectives: to work out the efficacy of (Sofosbuvir/ledipasvir) in treating children with HCV infection. Patients and methods: Patients with positive HCV PCR, aged 7 to 18 years were enrolled ... History and clinical…
Background: To detect any ocular surface changes with Sofosbuvir in Egyption patients with hepatitis C virus. Design: Continuous audit over 3 months for patients enrolled for Sofosbuvir therapy. Participants ... total…
individuals is considered a priority. Objectives: to evaluate the safety and efficacy of DAAs (sofosbuvir & daclatasvir) in treating chronic HCV in HCV-HIV co-infected Egyptian patients. Patients and methods ... were…
only interferon-free therapies are more challenging but also progression to cirrhosis is faster. Sofosbuvir, a NS5B nucleoside HCV polymerase inhibitor is one of the direct antiviral agents that ... pangenotypic…
medication accustomed treat viral hepatitis. It's a fixeddose combination of ledipasvir and sofosbuvir. Cure rates are ninety four to ninety nine in individuals infected with viral hepatitis virus ... safe for the baby…
lesser degree, a ventricular hyperexcitability, occurring after treatment with a combination of sofosbuvir plus ledispavir administered to treat a chronic Hepatitis C virus infection (HCV). The correction appeared…
public health issue. Mongolia is one of the first countries that registered Ledipasvir/Sofosbuvir (LDV/SOF) regimen from developing countries. By the support of Access program run by Gilead Sciences ... outcome of…
Sofosbuvir is a NS5B polymerase inhibitor with effective pan-genotypic coverage and approved for use in genotype IV. With the availability of both the brand drug (Sovaldi- Gilead ... this pilot study, we found that both…
carcinoma and decompensated liver disease, and minimizing the cases that require transplantation [6, 7]. Sofosbuvir is indicated for treatment of HCV genotypes 1, 2, 3 and 4. It is fixed ... effective and well tolerated…
Objective: A strategic quantitative analysis of Ledipasvir (LEDI) and Sofosbuvir (SOF) has been developed in Bulk and pharmaceutical (Tablet) dosage form with a reliable, Precise and sensitive First-Order Derivative
treatment administering DAAs which have high genetic barriers to resistance. In that point, ledipasvir/sofosbuvir (LDV/SOF) is recommended for treatment-naive or treatment-experienced patients with genotype
work, a stability indicating and validated UPLC method has been developed for estimation of Sofosbuvir (API) in bulk and its formulations (Sovaldi®). The chromatographic separation was achieved on a Waters
treatment-experienced with pegylated interferon- ribavirin was treated with 12-week course of ledipasvir/sofosbuvir and ribavirin. Three months after completing the treatment, virological relapse was occurred. Molecular…
step in personalized HCV therapy and pharmacogenomics. Methods: CHC Egyptian patients were received sofosbuvir (SOF) plus pegylated interferon (PEG-IFN) and ribavirin (RBV) for 12 weeks. A total
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.